The α2 adrenergic antagonist fipamezole improves quality of levodopa action in parkinsonian primates

Movement Disorders

Volumn 25, Issue 13, 2010, Pages 2084-2093

  Johnston, Tom H ^a   Fox, Susan H ^b   Piggott, Matthew J ^c   Savola, Juha Matti ^d   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Santhera Pharmaceuticals   (Switzerland)

Author keywords

Dyskinesia; MPTP primate; On time; Parkinson's disease; Wearing off

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; FIPAMEZOLE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; IMIDAZOLE DERIVATIVE; INDAN DERIVATIVE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DISABILITY SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG QUALITY; DYSKINESIA; FEMALE; LOW DRUG DOSE; MACACA; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANIMAL; DISABILITY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; MACACA FASCICULARIS; METHODOLOGY; MOTOR ACTIVITY; PARKINSONISM; TIME;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; IMIDAZOLES; INDANS; LEVODOPA; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; TIME FACTORS;

EID: 78649377976     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23172     Document Type: Article

References (52)

1. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
2. Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology 2009;72:S65-S73.
3. Bezard E, Baufreton J, Owens G, et al. Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus. FASEB J 2003;17: 2337-2338.
4. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956-963.
5. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
6. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
7. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008;7:927-938.
8. Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp Neurol 2005;191:243-250.
9. Dekundy A, Lundblad M, Danysz W, Cenci MA. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007;179:76-89.
10. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15:120-132.
11. Domino EF, Ni L, Colpaert F, Marien M. Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys. Recept Channels 2003;9:335-338.
12. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
13. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999;14:744-753.
14. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-650.
15. Dimitrova T, Bara-Jimenez W, Savola JM, Encarnacion EV, Mouradian MM, Chase TN. Alpha-2 adrenergic antagonist effects in Parkinson's disease. Mov Disord 2009;24 (Suppl 1): Mo-199, S261.
16. FJORD-Study-Group. Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease (Fjord). ClinicalTrials.gov Identifier: NCT00559871, 2008.
17. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18:872-883.
18. Fox SH, Lang AE, Brotchie JM. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord 2006;21:1578-1594.
19. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:336-337.
20. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebocontrolled trial. Mov Disord 2007;22:179-186.
21. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001;58:1660-1668.
22. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
23. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S., Marsden D, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Florham Park, New Jersey: Macmillan Healthcare Information; 1987. p 153-163.
24. Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008;60:57-66.
25. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
26. Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 2009;328:276-283.
27. Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions- report of a workshop. Mov Disord 1998;13:759-767.
28. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 2008;23: 2398-2403.
29. Hung SW, Adeli GW, Arenovich T, Fox SH, Lang AE. Patient perception of dyskinesias in Parkinson's disease. Neurology 2007;68 (Suppl 1):64.
30. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23 (Suppl 3):S580-S584.
31. Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 2007;30:236-243.
32. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-371.
33. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43:S23-S27.
34. De La Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
35. Ng KY, Chase TN, Colburn RW, Kopin IJ. Dopamine: stimulation-induced release from central neurons. Science 1971;172: 487-489.
36. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
37. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998;51:S30-S35.
38. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
39. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopainduced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
40. Crittenden JR, Cantuti-Castelvetri I, Saka E, et al. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci USA 2009;106:2892-2896.
41. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopainduced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
42. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009;72:1211-1216.
43. Fox S, Silverdale M, Kellett M, et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord 2004; 19:554-560.
44. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57:1829-1834.
45. Lewitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302.
46. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopainduced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
47. Scheinin M, Lomasney JW, Hayden-Hixson DM, et al. Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 1994;21:133-149.
48. Rosin DL, Talley EM, Lee A, et al. Distribution of alpha 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol 1996;372:135-165.
49. Holmberg M, Scheinin M, Kurose H, Miettinen R. Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 1999;93:1323-1333.
50. Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoaminedepleted rat. Br J Pharmacol 1999;128:1577-1585.
51. Alachkar A, Brotchie J, Jones OT. alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata. Neurosci Lett 2006;395:138-142.
52. Yavich L, Sirvio J, Haapalinna A, Ylinen A, Mannisto PT. Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 2003;462:83-89.